



Continuing Medical Education
Yale CME

Digestive Diseases Research Seminar
*Presented by Yale School of Medicine,
Department of Internal Medicine, and Section of Digestive Diseases*

Single cell resolution of neuroinflammation triggered by sphingolipids

Venkata (Sekhar) Boddupalli, PhD

Associate Research Scientist in Medicine
Department of Internal Medicine, Section of Digestive Diseases
Yale School of Medicine

Tuesday, March 29, 2022
5:00 - 6:00 pm

<https://zoom.us/j/93906449398?pwd=TmEzeTk5YjVSNjUyQms3SHh3N3ZZUT09&from=addon>

Host: Pramod Mistry, MBBS, PhD

Course Directors: Yasuko Iwakiri, PhD and Joseph Lim, MD

To record your attendance to this activity, text the Activity Code (29441) to 203-442-9435.

There is no corporate support for this activity. **Accreditation:** The Yale School of Medicine is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. **Target Audience:** YSM faculty, fellows, nurses, residents, medical students, staff, and other health care providers. **Designation Statement:** The Yale School of Medicine designates this live activity for 1 AMA PRA Category 1 Credit(s)[™]. Physicians should only claim the credit commensurate with the extent of their participation in the activity. **Needs assessment:** The mechanisms of neurodegeneration due to *Gba* mutations remain unclear and there are no effective therapies or pre-symptomatic biomarkers. Using single cell resolution of brain in cell-specific *Gba* deficiency models in mice displaying early- and late-onset Gaucher disease associated neurodegenerative disease, we found that cellular accumulation of glucosylceramide (GluCer) and glucosylsphingosine (GlcSph) triggered neuroinflammation orchestrated by lipid-laden microglia displaying enrichment of disease-associated microglia signature genes. our findings reveal that the complex multidimensional pattern of neuroinflammation and neurodegeneration involving diverse cell types in *Gba* deficiency can be targeted by potent brain penetrant inhibitor of glucosylceramide synthase. **Objectives:** To identify components of *Gba*-associated neuroinflammation, including immune cell subsets and activated pathways and identify therapeutic targets. To evaluate brain-penetrant inhibitor of GCS as a therapeutic strategy in both early and late onset *Gba* deficiency models to assess its impact on reducing cellular glycosphingolipids neuroinflammation and neurodegeneration while elucidating temporospatial cellular events. To identify biomarkers of pre-symptomatic disease in Gaucher disease patients who are at higher risk of developing neurodegenerative disease. **Faculty Disclosures:** None of the faculty/planners for this educational activity have relevant financial relationship(s) to disclose with ineligible companies. It is the policy of Yale School of Medicine, Continuing Medical Education, to ensure balance, independence, objectivity, and scientific rigor in all its educational programs. All faculty participating as speakers in these programs are required to disclose any relevant financial relationship(s) they (or spouse or partner) have with a commercial interest that benefits the individual in any financial amount that has occurred within the past 12 months; and the opportunity to affect the content of CME about the products or services of the commercial interests. The Center for Continuing Medical Education will ensure that any conflicts of interest are resolved before the educational activity occurs. **This course will fulfill the licensure requirement set forth by the State of Connecticut.**